Please assess the completion status of the following clinical trial:

Trial Title: Frovatriptan and Menstrual Migraine

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female~* Regular Menstrual Phase~* Menstrual Migraine~* No significant medical history (Significant medical history of such as seizure disorder, diabetes, alcoholism, cardiac disease including coronary artery disease, psychiatric problems; drug addiction, respiratory problems, liver disease, etc.)~* No significant medication history, except for migraine~* All patients will be currently taking or have previously taken triptan medications for migraine~* Weight, \<285 pounds~* Not claustrophobic~* No contraindication to taking triptans~Exclusion Criteria:~* Age \<18~* Significant medical problems (aside from pain before, during and after migraine episodes)~* Positive drug of abuse screen (excluding medications currently prescribed for their clinical condition, e.g. opioids, benzodiazepines, etc.)~* Positive alcohol screen~* Women taking oral contraceptives~* Claustrophobia~* History of dermatological hypersensitivity in the facial area~* Positive history of cardiac problems/ abnormalities seen in EKG at initial screening visit~* Pregnancy~* Sensory loss detected on Quantitative Sensory Testing at screening~* Significant alcohol history (ingestion of 5 or more glasses (\> 40 oz) of alcohol per week)~* Metal implants of any type (including dental bridges, crowns, retainers, orthodontic devices e.g. braces, etc.)~* Tattoos containing metallic ink on the neck, shoulders, upper arm and head (which could become heated up in the scanner, and potentially cause blistering or burning)~* Cardiac pacemakers~* Aneurysm clips and other vascular stents, filters, clips or other devices~* Prosthetic heart valves~* Other prostheses~* Neuro-stimulator devices~* Implanted infusion pumps~* Cochlear (ear) implants~* Ocular (eye) implants or known metal fragments in eyes~* Exposure to shrapnel or metal filings (sheet metal workers, welders, and others)~* Other metallic surgical hardware in vital areas~* Use of any of the following medications:~* Propanolol/ Inderol~* SSRI's: citalopram/ Celexa, Lepraxo, paroxetine/ Paxil, fluoxetine/ Prozac, Sarafem, Symbyax, sertraline/ Zoloft, Fluvoxamine/ Luvox~* SNRI's: duloxetine/ Cymbalta, venlafaxine/ Effexor~* triptans: sumatriptan/ Imitrex, naratriptan/ Amerge, zolmitriptan/ Zomig, rizatriptan/ Maxalt, eletriptan/ Relpax, almotriptan/ Axert~* ergotamine type medicines: Bellergal, Cafergot, Ergomar, Wiraine, Migranal/ DHE45, Sansert~* ketoconazole (Nizoral, Fungoral)~* itraconazole (Sporanox)~* ritonavir (Norvir)~* erythromycin (Erythrocin)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Frovatriptan (Type: None): All subjects will be taking Frovatriptan tablets within 48 hours prior to the scan session (Visit 2).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy